Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts

被引:12
作者
Zhou, Juan [1 ]
Ye, Yuanxin [1 ]
Zeng, Shugen [1 ]
Zhou, Yi [1 ]
Mao, Zhigang [1 ]
Song, Xingbo [1 ]
Ying, Binwu [1 ]
Lu, Xiaojun [1 ]
Jiang, Hong [1 ]
Wang, Lanlan [1 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Lab Med, Chengdu 610064, Sichuan Provinc, Peoples R China
来源
PLOS ONE | 2013年 / 8卷 / 02期
基金
中国国家自然科学基金;
关键词
CHRONIC MYELOPROLIFERATIVE DISORDERS; TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; CLINICAL-SIGNIFICANCE; JAK2(V617F); ACTIVATION; JAK2V617F; MYELOFIBROSIS; GRANULOCYTES;
D O I
10.1371/journal.pone.0057856
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Non-reactive platelet counts elevation occurs mainly in myeloproliferative disorders (MPDs), which have been reported to be closely associated with JAK2 V617F mutation. Complete blood cell count (CBC) is essential in diagnosis of MPDs, however, the impact of JAK2 V617F mutation on the patients' hemogram variation remains not clear. Methods: JAK2 V617F mutation was detected by allele specific real-time quantitative fluorescence PCR (AS-qPCR). Results: Of the 402 non-reactive platelet elevating patients, JAK2 V617F mutation was detected in 222 (55.2%) patients. RBC counts, WBC counts, platelet-large contrast ratio (P-LCR), platelet distribution width (PDW) and mean platelet volume (MPV) were much higher in JAK2 V617F mutated patients, except platelet counts. In addition, when the patients were classified into subgroups by blood cell counts, it was found that JAK2 V617F mutation rate increased progressively with the increase of RBC counts and WBC counts, other than platelet counts. Furthermore, trilineage hyperplasia group showed highest JAK2 V617F mutation rate (93.26%), followed by the bilineage hyperplasia groups. Lastly, JAK2 V617F mutant allele burden was found much higher in polycythemia vera (PV) patients [median(P-25-P-75): 45.02%(35.12%-54.22%)] than in essential thrombocythemia (ET) patients [median(P-25-P-75): 28.23%(17.77%-41.66%)], and that it increased with WBC counts (r = 0.393, p = 0.000) and RBC counts(r = 0.215, p = 0.001), other than platelet counts (r = -0.051, p = 0.452). Further analysis revealed that in ET patients, JAK2 V617F mutant allele burden correlated with WBC counts and platelet counts positively, other than RBC counts, while in PV patients, it correlated with WBC counts and RBC counts positively, but not platelet counts. Conclusions: JAK2 V617F mutation occurs frequently in patients with non-reactive elevated platelet counts. The presence of JAK2 V617F mutation has great impact on hemogram variation, including RBC counts, WBC counts, platelet parameters and lineage hyperplasia, but not on platelet counts. Besides, JAK2 V617F mutant allele burden affects the blood cell proliferation pattern.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
    Nielsen, Camilla
    Birgens, Henrik S.
    Nordestgaard, Borge G.
    Kjaer, Lasse
    Bojesen, Stig E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (03): : 450 - 453
  • [22] JAK2 V617F Mutation Testing in Polycythemia Vera: Use and Impact in an Academic Practice
    Means, Robert T., Jr.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2008, 336 (04) : 327 - 329
  • [23] Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation
    Er, Tze-Kiong
    Lin, Sheng-Fung
    Chang, Jan-Gowth
    Hsieh, Li-Ling
    Lin, Shu-Kai
    Wang, Li-Hsuan
    Lin, Chin-Wen
    Chang, Chao-Sung
    Liu, Ta-Chih
    CLINICA CHIMICA ACTA, 2009, 408 (1-2) : 39 - 44
  • [24] The frequency of JAK2 V617F gen mutation and its associations with whole blood count parameters
    Unal, Kubranur
    Erdogan, Serpil
    Yilmaz, Fatma Meric
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2014, 39 (01): : 93 - 98
  • [25] Rapid detection of JAK2 V617F mutation using high-resolution melting analysis with LightScanner platform
    Qian, Jun
    Lin, Jiang
    Yao, Dong-Ming
    Chen, Qin
    Xiao, Gao-Fei
    Ji, Run-Bi
    Li, Yun
    Yang, Jing
    Qian, Zhen
    CLINICA CHIMICA ACTA, 2010, 411 (23-24) : 2097 - 2100
  • [26] New advances in the role of JAK2 V617F mutation in myeloproliferative neoplasms
    Zhang, Yongchao
    Zhao, Yue
    Liu, YuSi
    Zhang, Minyu
    Zhang, Jihong
    CANCER, 2024, 130 (24) : 4229 - 4240
  • [27] The JAK2 V617F Mutation in Pediatric Myeloproliferative Neoplasms: How and When?
    Langabeer, Stephen E.
    Smith, Owen P.
    McMahon, Corrina
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2014, 31 (02) : 138 - 139
  • [28] Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
    Zhang, Shu-Peng
    Li, Hui
    Lai, Ren-Sheng
    ONCOLOGY LETTERS, 2015, 9 (02) : 735 - 738
  • [29] Chronic neutrophilic leukemia with JAK2 V617F mutation: a case report
    Hu, Jiasheng
    Xu, Yanni
    Li, Zhe
    Hong, Xiuli
    Lu, Quanyi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (07): : 7482 - 7487
  • [30] The study of Jak2 V617F mutation in polycythemia vera with zebrafish model
    Ma, Alvin C. H.
    Cheung, Alice M. S.
    Ward, Alister C.
    Au, Wing-Yan
    Kwong, Yok-Lam
    Liang, Raymond
    Leung, Anskar Y. H.
    CELL RESEARCH, 2008, 18 (Suppl 1) : S141 - S141